Details for New Drug Application (NDA): 065214
✉ Email this page to a colleague
NDA 065214 describes CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, which is a drug marketed by B Braun and is included in one NDA. It is available from one supplier. Additional details are available on the CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER profile page.
The generic ingredient in CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER is cefoxitin sodium. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefoxitin sodium profile page.
The generic ingredient in CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER is cefoxitin sodium. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefoxitin sodium profile page.
Summary for 065214
| Tradename: | CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER |
| Applicant: | B Braun |
| Ingredient: | cefoxitin sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 065214
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER | cefoxitin sodium | INJECTABLE;INJECTION | 065214 | NDA | B. Braun Medical Inc. | 0264-3123 | 0264-3123-11 | 24 CONTAINER in 1 CASE (0264-3123-11) / 50 mL in 1 CONTAINER |
| CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER | cefoxitin sodium | INJECTABLE;INJECTION | 065214 | NDA | B. Braun Medical Inc. | 0264-3125 | 0264-3125-11 | 24 CONTAINER in 1 CASE (0264-3125-11) / 50 mL in 1 CONTAINER |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Mar 10, 2006 | TE: | AP | RLD: | Yes | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Mar 10, 2006 | TE: | AP | RLD: | Yes | ||||
Complete Access Available with Subscription
